Summary of Utilization Management (UM) Program Changes

July 2023

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
Filspari	sparsentan	Indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Initial criteria requires: 1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) as confirmed by a kidney biopsy 2) Patient is at risk of rapid disease progression [e.g., generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such as clinical risk scoring using the International IgAN Prediction Tool] 3) Used to reduce proteinuria; 4) Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.73 m2; 5) Patient has been on a minimum 90-day trial of a maximally tolerated doses of one of the following: a) An angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril) b) An angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan); 6) Medication will not be used in combination with any of the following: a) Angiotensin receptor blockers b) Endothelin receptor antagonists (ERAs) (e.g., ambrisentan, bosentan, Opsumit) c) Aliskiren; 7) Prescribed by or in consultation with a nephrologist	New	10/1/2023
Jaypirca	pirtobrutinib	For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton Tyrosine Kinase (BTK) inhibitor. Initial criteria requires: 1) Diagnosis of mantle cell lymphoma (MCL); 2) Disease is one of the following: Relapsed or Refractory; 3) Patient has received at least two prior therapies for MCL, one of which is a Bruton Tyrosine Kinase (BTK) inhibitor therapy [e.g., Imbruvica (ibrutinib), Calquence (acalabrutinib), Brukinsa (zanubrutinib)];	New	10/1/2023

		[Imbruvica (ibrutinib) listed as a drug example for Med D only] 4) Prescribed by or in consultation with an oncologist.		
Orserdu	elacestrant	For the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Initial criteria requires: 1) Diagnosis of breast cancer; 2) Disease is one of the following: Advanced or Metastatic; 3) Disease is estrogen receptor (ER)-positive; 4) Disease is human epidermal growth factor receptor 2 (HER2)-negative; 5) Presence of estrogen receptor (ESR1) mutation(s) as detected by an FDA-approved test; 6) Disease has progressed following at least one line of endocrine therapy [e.g., Faslodex (fulvestrant), Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)]; 7) Prescribed by or in consultation with an oncologist	New	10/1/2023
Kevzara	sarilumab	Treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Initial criteria requires: 1) Diagnosis of polymyalgia rheumatica (PMR); 2) One of the following: a) Patient has had an inadequate response to corticosteroids (e.g., prednisone) OR b) Patient cannot tolerate tapering of corticosteroids (e.g., prednisone); 3) Prescribed by or in consultation with a rheumatologist	Update	10/1/2023
Rebyota	fecal microbiota, live-jslm	Criteria requires: 1) Diagnosis of recurrent clostridioides difficile infection (CDI) as defined by both of the following: a) Presence of diarrhea defined as a passage of 3 or more loose bowel movements within a 24-hour period for 2 consecutive days b) A positive stool test for C.difficile toxin or toxigenic C.difficile 2) Patient is 18 years of age or older 3) Patient has a history of one or more recurrent episodes of CDI	Update	10/1/2023

		4) Both of the following: a) Patient has completed at least 10 consecutive days of one of the following antibiotic therapies between 24 to 72 hours prior to initiating Rebyota: oral vancomycin or Dificid (fidaxomicin) b) Previous episode of CDI is under control (e.g., less than 3 unformed/loose [i.e., Bristol Stool Scale type 6-7] stools/day for 2 consecutive days) 5) Prescribed by or in consultation with a gastroenterologist or infectious disease specialist		
Livmarli	maralixibat	Expanded indication: Treatment of cholestatic pruritus in patients with Alagille syndrome 3 months of age and older. Previously this was approved for patients age 1 year or age and older. Existing age criteria will be updated to require "Patient is 3 months of age or older."	Update	10/1/2023
Benlysta	belimumab	Guideline for subcutaneously administered product that can be self-administered. Initial criteria for Systemic Lupus Erythhematosis (SLE) requires: 1) Diagnosis of active lupus nepthritis 2) Autoantibody positive; 3) Age 18 years or older 4) Trial and failure, contraindication, or intolerance to two standard of care treatments for active SLE: hydroxychloroquine, corticosteroids, or immunosuppressants [such as methotrexate or azathioprine] 5) Currently receiving at least one standard of care treatment for active SLE: hydroxychloroquine, corticosteroids, or immunosuppressants [such as methotrexate or azathioprine] 6) Prescribed by or in consultation with a rheumatologist Initial criteria for Lupus nephritis requires: 1) Diagnosis of active lupus nephritis 2) Age 18 years or older 3) Currently receiving standard of care treatment for active lupus nephritis (such as corticosteroids with mycophenolate or cyclophosphamide) 4) Prescribed by or in consultation with a rheumatologist or nephrologist	New	10/1/2023
Furoscix	furosemide	Medical records and/or paid receipts will need to be submitted to confirm patient is on maintenance oral diuretic therapy.	Update	10/1/2023
Ferriprox	deferiprone	Updated guideline with approved age. Oral solution is approved for ages 3 and older.	Update	10/1/2023

Takhzyro	lanadelumab-flyo	Updated guideline with approved age. Takhzyro is approved for ages 2 and older.	Update	10/1/2023
Tegsedi	inotersen	Updated Neuropathy Impairment Score (NIS) score in to require between 10 and 130 for Tegsedi to align with the clinical trials. Removed "Patient has not had a liver transplant" in criteria.	Update	10/1/2023